



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Björn Nilsson

Art Unit : 1614

Serial No. : 10/618,868

Examiner : Unknown

Filed : July 14, 2003

Title : NOVEL COMPOUNDS AND THEIR USE

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. A check for \$180 in payment of the late submission fee of §1.17(p) is enclosed. Please apply any other charges or credits to Deposit Account No. 06-1050.

05/17/2006 BABRAHA1 00000081 10618868

01 FC:1886

180.00 OP

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate

Applicant : Björn Nilsson  
Serial No. : 10/618,868  
Filed : July 14, 2003  
Page : 2 of 2


Attorney's Docket No.: 13425-056002 / 00410-US -  
DIV

Respectfully submitted,

Date: May 9, 2006

John T. Kendall  
John T. Kendall, Ph.D.  
Reg. No. 50,680

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-056002	Application No. 10/618,868
	<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Björn Nilsson	
			Filing Date July 14, 2003	Group Art Unit 1614

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,447,931	09/05/1995	Baroni, et al.			

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB							

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AC	Andersson, K.-E. "Treatment of the overactive bladder: possible central nervous system drug targets." Urology 2002, 59 (Suppl 5A), 18-24.
	AD	Andersson, K-E: "Pharmacology of penile erection." Pharmacol. Rev. 2001, 53, 417-450.
	AE	Applegate CD, Tecott, LH. "Global increases in seizure susceptibility in mice lacking 5-HT2C receptors: A behavioural analysis." Exp. Neurol. 1998, 154, 522-530.
	AF	Arjona, A. A.; Pooler, A. M.; Lee, R. K.; Wurtman, R. J. "Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs." Brain. Res. 2002, 951, 135-140.
	AG	Chojnacka-Wojcik E, Klodzinska A, Deren-Wesolek A. "Involvement of 5-HT2C receptors in the m-CPP-induced antinociception in mice." Pol J Pharmacol. 1994 Sep-Oct;46(5):423-8.
	AH	Cryan JF, Lucki I. . "Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors." J Pharmacol Exp Ther. 2000 Dec;295(3):1120-6.
	AI	de Groat, W.C. "Influence of central serotonergic mechanisms on lower urinary tract function." Urology 2002, 59 (Suppl. 5A), 30-36.
	AJ	Dhonnchadha BAN, Bourin M, Hascoet M. "Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety." Behavioural Brain Research 2003 140 (1-2): 203-214.
	AK	Grottick AJ, Corrigan WA, Higgins GA. "Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine." Psychopharmacology (Berl). 2001 Sep;157(3):292-8.
	AL	Grottick AJ, Fletcher PJ, Higgins GA. "Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior." J Pharmacol Exp Ther. 2000 Dec;295(3):1183-91.
	AM	Guarneri, L. et al. "The effects of m-CPP on bladder voiding contractions in rats are mediated by the 5-HT2A/5-HT2C receptors." NeuroUrol. Urodyn. 1996, 15, 316-317.
	AN	Heisler LK, Chu HM, Tecott LH. "Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice." Ann NY Acad Sci 1998, 861, 74-78.
	AO	Isaac M. "The 5-HT2C receptor as a potential therapeutic target for the design of antiobesity and antiepileptic drugs." Drugs Future 2001, 26, 383-393.
	AP	Millan, MJ, Peglion, JL, Lavielle G, Perrin-Monneyron S: 5-HT2C receptors mediate penile rections in rats: actions of novel and selective agonists and antagonists." Eur. J. Pharmacol. 1997, 325, 9-12.
	AQ	Moreau, J.-L.; Boes, M.; Jenck, F.; Martin, J. R.; Mortas, P.; Wichmann, J. "5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats." European Neuropsychopharmacology 1996 6(3), 169-175.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-056002	Application No. 10/618,868
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Björn Nilsson	
		Filing Date July 14, 2003	Group Art Unit 1614
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AR	Piesla MJ, Comery TA, Brennan JA, Welmaker GS, Rosenzweig-Lipson S, Marquis KL. "Atypical antipsychotic-like effects of 5-HT <sub>2C</sub> agonists." Schizophrenia Res. 49 (1-2): 95-95 Sp. Iss. SI Suppl. S, APR 15, 2001.
	AS	Pomerantz SM. "5-HT <sub>1A</sub> and 5-HT <sub>1C/D</sub> receptor agonists produce reciprocal effects on male sexual behavior of rhesus monkeys." Eur. J. Pharmacol. 1993, 243, 227-234.
	AT	Porter, R. H.; Benwell, K. R.; Lamb, H.; Malcolm, C. S.; Allen, N. H.; Revell, D. F.; Adams, D. R.; Sheardown, M. J. "Functional characterization of agonists at recombinant human 5-HT <sub>2A</sub> , 5-HT <sub>2B</sub> and 5-HT <sub>2C</sub> receptors in CHO-K1 cells." Br. J. Pharmacol. 1999, 128, 13-20.
	AU	Pranzatelli, M.R. et al. "Identification of spinal 5-HT <sub>1C</sub> binding sites in the rat: characterization of [3H]mesulergine binding." J. Pharmacol. Exp. Ther. 1992, 261, 161-165.
	AV	Steers W.D. et al. "Effects of m-chlorophenylpiperazine on penile and bladder function in rats." Am. J. Physiol. 1989, 257, R1441-R1449.
	AW	Steers, W.D. et al. "Effects of serotonergic agonists on micturition and sexual function in the rat." Drug Dev. Res. 1992, 27, 361-375.
	AX	Szele, FG, Murphy DL, Garrick NA: "Effects of fenfluramine, m-chlorophenylpiperazine, and other serotonin-related agonists and antagonists on penile erections in nonhuman primates." Life Sci. 1988, 43, 1297-1303.
	AY	Tecott, LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius, D. "Eating disorder and epilepsy in mice lacking 5-HT <sub>2C</sub> serotonin receptors." Nature 1995, 374, 542-546.
	AZ	Testa, R. et al. "Effect of different 5-hydroxytryptamine receptor subtype antagonists on the micturition reflex in rats." BJU Int. 2001, 87, 256-264.
	AAA	Upton N, Stean T, Middlemiss D, Blackburn T, Kennett G. "Studies on the role of 5-HT <sub>2C</sub> and 5-HT <sub>2B</sub> receptors in regulating generalized seizure threshold in rodents." Eur. J. Pharmacol. 1998, 359, 33-40.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	